ATC Group: L01FD01 Trastuzumab

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of L01FD01 in the ATC hierarchy

Level Code Title
1 L Antineoplastic and immunomodulating agents
2 L01 Antineoplastic agents
3 L01F Monoclonal antibodies and antibody drug conjugates
4 L01FD HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors
5 L01FD01 Trastuzumab

Active ingredients in L01FD01

Active Ingredient Description
Trastuzumab

Trastuzumab is a recombinant humanised IgG1 monoclonal antibody against the human epidermal growth factor receptor 2 (HER2). ฮคrastuzumab has been shown, in both in vitro assays and in animals, to inhibit the proliferation of human tumour cells that overexpress HER2.

Related product monographs

Title Information Source Document Type  
HERCESSI Solution for injection FDA, National Drug Code (US) MPI, US: SPL/PLR
ONTRUZANT Powder for concentrate for solution for infusion European Medicines Agency (EU) MPI, EU: SmPC

Medicines in this ATC group

Cyprus (CY)

Hong Kong (HK)

Japan (JP)

Singapore (SG)

Tunisia (TN)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.